ArticleJournal of neuroscience research2020
The BioLuminescent-OptoGenetic in vivo response to coelenterazine is proportional, sensitive, and specific in neocortex.
Article in Journal of neuroscience research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Article
- Control of Synaptic Communication through Molecularly Engineered Bioluminescence Light Emission and Sensing.bioRxiv : the preprint server for biology · 2025Article
- A Bioluminescent Activity Dependent (BLADe) Platform for Converting Intracellular Activity to Photoreceptor Activation.bioRxiv : the preprint server for biology · 2025Article
- Presymptomatic targeted circuit manipulation for ameliorating Huntington's disease pathogenesis.iScience · 2025Article
- Strength of activation and temporal dynamics of bioluminescent-optogenetics in response to systemic injections of the luciferin.NeuroImage · 2024Article
- Presymptomatic Targeted Circuit Manipulation for Ameliorating Huntington's Disease Pathogenesis.bioRxiv : the preprint server for biology · 2024Article
- Bioluminescent Systems for Theranostic Applications.International journal of molecular sciences · 2024Review
- Toward a brighter constellation: multiorgan neuroimaging of neural and vascular dynamics in the spinal cord and brain.Neurophotonics · 2024Article
- Engineering luminopsins with improved coupling efficiencies.Neurophotonics · 2024Article
- BioLuminescent OptoGenetics in the choroid plexus: integrated opto- and chemogenetic controlNeurophotonics · 2024Article
- Towards a Brighter Constellation: Multi-Organ Neuroimaging of Neural and Vascular Dynamics in the Spinal Cord and Brain.bioRxiv : the preprint server for biology · 2023Article
- Engineering luminopsins with improved coupling efficiencies.bioRxiv : the preprint server for biology · 2023Article
- Coelenterazine-Type Bioluminescence-Induced Optical Probes for Sensing and Controlling Biological Processes.International journal of molecular sciences · 2023Review
- Experimental approaches for manipulating choroid plexus epithelial cells.Fluids and barriers of the CNS · 2022Review
- Bioluminescent Optogenetics: A Novel Experimental Therapy to Promote Axon Regeneration after Peripheral Nerve Injury.International journal of molecular sciences · 2021Article
- Selective postnatal excitation of neocortical pyramidal neurons results in distinctive behavioral and circuit deficits in adulthood.iScience · 2021Article
- Restoring Function After Severe Spinal Cord Injury Through BioLuminescent-OptoGenetics.Frontiers in neurology · 2021Article
- Bioluminescence-Driven Optogenetics.Life (Basel, Switzerland) · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
BioLuminescent (BL) light production can modulate neural activity and behavior through co-expressed OptoGenetic (OG) elements, an approach termed "BL-OG." Yet, the relationship between BL-OG effects and bioluminescent photon emission has not been characterized in vivo. Further, the degree to which BL-OG effects strictly depend on optogenetic mechanisms driven by bioluminescent photons is unknown. Crucial to every neuromodulation method is whether the activator shows a dynamic concentration range driving robust, selective, and nontoxic effects. We systematically tested the effects of four key components of the BL-OG mechanism (luciferin, oxidized luciferin, luciferin vehicle, and bioluminescence), and compared these against effects induced by the Luminopsin-3 (LMO3) BL-OG molecule, a fusion of slow burn Gaussia luciferase (sbGLuc) and Volvox ChannelRhodopsin-1 (VChR1). We performed combined bioluminescence imaging and electrophysiological recordings while injecting specific doses of Coelenterazine (substrate for sbGluc), Coelenteramide (CTM, the oxidized product of CTZ), or CTZ vehicle. CTZ robustly drove activity in mice expressing LMO3, with photon production proportional to firing rate. In contrast, low and moderate doses of CTZ, CTM, or vehicle did not modulate activity in mice that did not express LMO3. We also failed to find bioluminescence effects on neural activity in mice expressing an optogenetically nonsensitive LMO3 variant. We observed weak responses to the highest dose of CTZ in control mice, but these effects were significantly smaller than those observed in the LMO3 group. These results show that in neocortex in vivo, there is a large CTZ range wherein BL-OG effects are specific to its active chemogenetic mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.